Daiwa Securities Group
NMRA icon

Daiwa Securities Group’s Neumora Therapeutics NMRA Stock Holding History

Daiwa Securities Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-533
Closed -$1K – 1351
2025
Q4 		$1K Hold
533
– – ﹤0.01% 1349
2025
Q3 		$1K Hold
533
– – ﹤0.01% 1313
2025
Q2 		$0 Hold
533
– – ﹤0.01% 1327
2025
Q1 		$1K Hold
533
– – ﹤0.01% 1237
2024
Q4 		$6K Buy
+533
New +$6.39K ﹤0.01% 1155

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Daiwa Securities Group's NMRA Position: Q1 2026 in Review

Daiwa Securities Group sold out of Neumora Therapeutics (NMRA) in Q1 2026, closing a stake of 533 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in NMRA in Q4 2024 and held it in 5 quarters. The position peaked at $6K in Q4 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Daiwa Securities Group reported no remaining Neumora Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 533 Neumora Therapeutics shares in Q1 2026, an estimated $1K.
  • Daiwa Securities Group first reported a position in Neumora Therapeutics in Q4 2024 and held it in 5 quarters.
  • Daiwa Securities Group's Neumora Therapeutics position peaked at $6K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.